Feeding disorder

Tonix Pharmaceuticals Announces Issuance of EU Patent Covering Intranasal Potentiated Oxytocin (TNX-1900) for the Treatment of Pain

Retrieved on: 
Wednesday, October 4, 2023
University of Geneva, Patent, Insulin resistance, Tonix Pharmaceuticals, Migraine, University, Magnesium, Prader–Willi syndrome, European Patent Office, INSERM, Feeding disorder, Oxytocin, IP, EPO, Patient, European Patent Convention, Pharmaceutical industry

CHATHAM, N.J., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that the European Patent Office (EPO) issued European Patent No. 3242676 to the Company on October 4, 2023. The patent, entitled “Magnesium-Containing Oxytocin Formulations and Methods of Use”, claims methods and compositions for treating pain, including migraine headaches, using intranasal magnesium-containing oxytocin formulations. This patent, excluding possible patent term extensions, is expected to provide Tonix with market exclusivity in the member states of the European Patent Office until 2036. The U.S. Patent and Trademark Office (USPTO) has previously issued U.S. Patents No. 9,629,894 and 11,389,473 which are expected to provide market exclusivity in the U.S. until 2036.

Key Points: 
  • CHATHAM, N.J., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that the European Patent Office (EPO) issued European Patent No.
  • The patent, entitled “Magnesium-Containing Oxytocin Formulations and Methods of Use”, claims methods and compositions for treating pain, including migraine headaches, using intranasal magnesium-containing oxytocin formulations.
  • This patent, excluding possible patent term extensions, is expected to provide Tonix with market exclusivity in the member states of the European Patent Office until 2036.
  • “We believe this European patent combined with the U.S. issuance provides a strong patent position for TNX-1900 as we move forward in clinical development for the treatment of chronic migraine,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals.

Feeding Matters, Emory University and Children's Healthcare of Atlanta to Host Groundbreaking Consensus Summit on PFD and ARFID

Retrieved on: 
Thursday, July 27, 2023
Consensus, ARFID, Emory University, University of Virginia School of Nursing, Communication, University, Eating disorder, Pediatrics, Parent, Eating, Feeding disorder, Hope, Research, University of North Carolina at Greensboro, Doctor of Philosophy, Associate, Disorder, Child, Head, School, Children's Healthcare of Atlanta, Nursing, Diagnosis, PFD, Environment, Avoidant/restrictive food intake disorder

PHOENIX, July 27, 2023 /PRNewswire-PRWeb/ -- Feeding Matters, a leading nonprofit organization dedicated to advancing the understanding and treatment of pediatric feeding disorder, is proud to announce its affiliation with Emory University, a renowned academic institution at the forefront of medical research, and Children's Healthcare of Atlanta, the only freestanding pediatric health system in Georgia, for the upcoming Consensus Summit on Pediatric Feeding Disorder (PFD) and Avoidant/Restrictive Food Intake Disorder (ARFID).

Key Points: 
  • Dr. Estrem's expertise lies in pediatric healthcare research, with a specific focus on pediatric feeding difficulties.
  • Inspired by her own child, Dr. Estrem has pursued a career in feeding research, making her a valuable contributor to facilitate the summit.
  • Pediatric feeding disorder (PFD) and Avoidant/Restrictive Food Intake Disorder (ARFID) are complex conditions that significantly impact the lives of children and adults alike.
  • Feeding Matters' long-standing commitment to consensus building and collaboration has been instrumental in driving progress in the field of pediatric feeding disorder.

The 10th Annual International Pediatric Feeding Disorder Conference Unites 58 prominent Feeding and Therapy experts and more than 80 authors

Retrieved on: 
Friday, March 17, 2023
CE, Loss, International, University, Life, Francine Shapiro, Ventricular septal defect, Psychiatric-mental health nurse practitioner, PLLC, International Pediatric Nephrology Association, Trauma, Feeding disorder, Research, Private practice, University of North Carolina at Pembroke, PMHNP, APRN, Grief, Publication, Patient, Child, Matter, EMDR, PFD, Fairfield University, Family, Conference, Nursing, PHOENIX

PHOENIX, March 16, 2023 /PRNewswire-PRWeb/ -- Arizona-based nonprofit Feeding Matters, the first organization in the world dedicated to advancing the system of care for pediatric feeding disorder (PFD) is proud to host the upcoming 10th annual International Pediatric Feeding Disorder Conference (IPFDC). The IPFDC 2023 will be streamed live April 13-14, 2023, with pre-conference events on April 12, and will offer the most diverse group of speakers and lightning talk authors to date. All sessions will be available on-demand through May 31, 2023.

Key Points: 
  • Arizona-based nonprofit Feeding Matters, the first organization in the world dedicated to advancing the system of care for pediatric feeding disorder (PFD) is proud to host the upcoming 10th annual International Pediatric Feeding Disorder Conference (IPFDC).
  • PHOENIX, March 16, 2023 /PRNewswire-PRWeb/ -- Arizona-based nonprofit Feeding Matters, the first organization in the world dedicated to advancing the system of care for pediatric feeding disorder (PFD) is proud to host the upcoming 10th annual International Pediatric Feeding Disorder Conference (IPFDC).
  • This year's conference will bring together a lineup of the pediatric feeding community's foremost experts, leaders, and contributors.
  • To secure your registration or see the complete schedule with session descriptions for the year's most prolific and informative pediatric feeding conference, visit International Pediatric Feeding Disorder Conference.

NewcleusGives Focuses on the Kids

Retrieved on: 
Thursday, January 5, 2023
Search Engine Marketing, Other Professional Services, Other Communications, Insurance, Public Relations, Investor Relations, Finance, Marketing, Consulting, Small Business, Banking, Communications, Professional Services, Philanthropy, Fund Raising, Foundation, Other Philanthropy, Research, Organization, Volunteering, Book, Feeding disorder, Workplace, Midcontinent Independent System Operator, Organic, Boys & Girls Club, Management, Toy, Newcleus

In 2022, Newcleus volunteers prepared a sports field for disabled kids, supported kid’s cancer research and donated to programs for low-income high school students, Boys and Girls Clubs, kids with feeding disorders and after school care.

Key Points: 
  • In 2022, Newcleus volunteers prepared a sports field for disabled kids, supported kid’s cancer research and donated to programs for low-income high school students, Boys and Girls Clubs, kids with feeding disorders and after school care.
  • NewcleusGives is a workplace giving program with a mission to direct philanthropy to helping children and families, touching organizations nearby and across the country.
  • NewcleusGives elevates company culture, increases connection among team members, supports clients and their communities, empowers charities and inspires workplace and community engagement.
  • NewcleusGives connects all of the volunteer activities Newcleus employees have supported over the years, making them stronger while collaborating to make a greater impact.

FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS (FAST) ANNOUNCES SALE OF ITS SHARES IN GENETX TO ULTRAGENYX

Retrieved on: 
Monday, July 18, 2022
Research, Acquisition, Epilepsy, Therapy, View, Foundation, Trial of the century, AS, United Kingdom, FAST, Caregiver, Genetic disorder, Biotechnology, Multimedia, Industry, Sale, Government budget balance, Partnership, UBE3A, Feeding disorder, University, Pharmaceutical industry, Cryptocurrency, Ultragenyx, Angelman syndrome

AUSTIN, Texas, July 18, 2022 /PRNewswire/ -- The Foundation for Angelman Syndrome Therapeutics (FAST) today announced that Ultragenyx Pharmaceutical Inc. has exercised its exclusive option to acquire GeneTx Biotherapeutics LLC, a biotechnology company founded and launched by FAST, and has closed on the acquisition. Since 2019, GeneTx and Ultragenyx have partnered on the clinical development of GTX-102. The acquisition signals a critical step forward in support of FAST's mission to foster the development of treatments for Angelman syndrome (AS), a rare and debilitating neurogenetic disorder that impacts approximately one in 15,000 individuals. 

Key Points: 
  • Since 2019, GeneTx and Ultragenyx have partnered on the clinical development of GTX-102.
  • In 2017, FAST launched GeneTx Biotherapeutics LLC to develop an investigational antisense oligonucleotide, GTX-102, for the treatment of AS.
  • Angelman Syndrome is a rare genetic disorder characterized by developmental delays, epilepsy, and problems with motor coordination and balance.
  • FAST is a Section 501(c)(3) non-profit research organization narrowly focused on funding research that holds the greatest promise of treating Angelman Syndrome.

Mitsubishi Tanabe Pharma America Presents 48-Week Results from Global Phase 3 Safety Clinical Study of RADICAVA ORS® (edaravone), an Oral Treatment for ALS

Retrieved on: 
Wednesday, June 1, 2022
McGill University Health Centre, Prognosis, Precision medicine, IV, SB, A03, Multimedia, ORS, Mitsubishi Tanabe Pharma, History, Edaravone, Pneumonia, Headache, Diabetic ketoacidosis, Bruise, Breathe Me, Food, Average absolute deviation, Central nervous system, Ageing, Back pain, Solution, Red, BST, MTPA, Failure rate, Suicide, Hypersensitivity, Anaphylaxis, ALS, Prevalence, Dysphagia, SD, Constipation, Death, Erythema multiforme, Facebook, Fatigue, Week, Amyotrophic lateral sclerosis, LinkedIn, Weakness, Feeding disorder, Disease, Policy, FDA, A01, Hives, FRCP, Twitter, Water, Hospital, Safety, Medical device, Pharmaceutical industry, Dietary supplement, Generic drug, Communications satellite, Fine chemical, Patient

JERSEY CITY, N.J., June 1, 2022 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced 48-week results from the global Phase 3 open-label, multi-center clinical trial (MT-1186-A01) assessing the safety and tolerability of RADICAVA ORS® (edaravone) in patients with amyotrophic lateral sclerosis (ALS). Details about the findings will be presented at the European Network to Cure ALS (ENCALS) Meeting 2022, being held in Edinburgh, Scotland, from June 1-3.

Key Points: 
  • "These data reinforce the potential significance of RADICAVA ORS and its important role in the treatment of this devastating disease."
  • Patients should not eat or drink (except water) within one hour after taking RADICAVA ORS.1
    Edaravone was discovered and developed for ALS by Mitsubishi Tanabe Pharma Corporation (MTPC) and Mitsubishi Tanabe Pharma Development America, Inc (MTDA), commercialized in the U.S. by Mitsubishi Tanabe Pharma America, Inc (MTPA).
  • About Mitsubishi Tanabe Pharma America, Inc.
    Based in Jersey City, N.J., Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation's (MTPC) 100 percent owned U.S. holding company, Mitsubishi Tanabe Pharma Holdings America, Inc.
  • MTDA is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation's 100 percent-owned U.S. holding company, Mitsubishi Tanabe Pharma Holdings America, Inc. For more information, please visit https://mt-pharma-development-america.com/ .

BEYOND THERAPY FOR KIDS OPENS GULFPORT OUTPATIENT CLINIC

Retrieved on: 
Monday, March 28, 2022
University, Anatomical pathology, Gulfport, Benchmark, Clinic, Occupational therapy, Beyond Therapy, Upstream, Multimedia, Sensory processing disorder, Pediatrics, University of Mississippi Medical Center, Biology, McCaffery, Feeding disorder, Hospital, Medicine, Tupelo

 GULFPORT, Miss., March 28, 2022 /PRNewswire/ -- Beyond Therapy for Kids, which provides physical, occupational and speech therapy for children, opened an outpatient clinic today at 1423 Magnolia St., Suite D.

Key Points: 
  • GULFPORT, Miss., March 28, 2022 /PRNewswire/ -- Beyond Therapy for Kids, which provides physical, occupational and speech therapy for children, opened an outpatient clinic today at 1423 Magnolia St., Suite D.
    The clinic operates 8 a.m. to 5 p.m. weekdays and offers in-clinic and telehealth evaluations and visits.
  • Clinic director Robin McCaffery earned a bachelor's degree in biology from the University of Southern Mississippi and a bachelor's degree in occupational therapy from the University of Mississippi Medical Center.
  • Beyond Therapy, which also has clinics in Hattiesburg, Meridian, Ridgeland and Tupelo,is part of the Upstream Rehabilitation family of clinical care.
  • Another Upstream brand, BenchMark Physical Therapy, opened an outpatient clinic next to the Beyond Therapy's new Gulfport clinic, in Suite F, on March 14.

American Friends of ALYN Hospital's New Webinar Series to Launch During Women's History Month

Retrieved on: 
Monday, March 14, 2022
ALYN Hospital, Spinal cord injury, Women's History Month, Master's degree, Patient, COVID-19, Q&A, Burns, EST, Friends, Brain, Cerebral palsy, Functional diversity (disability), Never Letting Go, Awareness, Hope, Birth, Rehabilitation, Research, Feeding disorder, Align, Harvard University, Whole, Degenerative disease, Medicine, Residential care

The first installment will take place on March 22, and, in celebration of Women's History Month, will feature ALYN Hospital's Director General, Dr. Maurit Beeri.

Key Points: 
  • The first installment will take place on March 22, and, in celebration of Women's History Month, will feature ALYN Hospital's Director General, Dr. Maurit Beeri.
  • "We say that ALYN is Israel's best kept secret," said Maayan Aviv, Executive Director of American Friends of ALYN.
  • "With the launch of this new webinar series, our hope is to show more people a behind-the-scenes look into the life changing work at ALYN.
  • Since 1934, American Friends of ALYN Hospital (AFAH) has supported ALYN Hospital in Israel.

The 8th Annual International Pediatric Feeding Disorder Conference Boasts More Than Thirty Internationally Renowned Feeding Experts

Retrieved on: 
Thursday, April 15, 2021
Infant feeding, Feeding disorder, Malnutrition

b'PHOENIX, April 15, 2021 /PRNewswire-PRWeb/ -- Arizona-based nonprofit Feeding Matters , the first organization in the world dedicated to advancing the system of care for pediatric feeding disorder (PFD) is proud to host the upcoming 8th annual International Pediatric Feeding Disorder Conference (IPFDC).

Key Points: 
  • b'PHOENIX, April 15, 2021 /PRNewswire-PRWeb/ -- Arizona-based nonprofit Feeding Matters , the first organization in the world dedicated to advancing the system of care for pediatric feeding disorder (PFD) is proud to host the upcoming 8th annual International Pediatric Feeding Disorder Conference (IPFDC).
  • This year\'s conference will bring together a lineup of more than 30 of the pediatric feeding community\'s foremost experts, leaders, and contributors.
  • That\'s why Feeding Matters is dedicated to creating a world where children with pediatric feeding disorder will thrive.
  • To learn more about pediatric feeding disorder, visit feedingmatters.org or follow us on Facebook, Instagram and YouTube at @FeedingMatters.\n'

The Journal of Pediatrics Publishes Promising Results & Potential from The Infant and Child Feeding Questionnaire Study

Retrieved on: 
Wednesday, June 17, 2020
Infant feeding, Eating disorders, Feeding disorder, Malnutrition, Pediatrics, Articles, Health, Human behavior, Enteral feeding

Participants' children were male and female aged between birth and 4 years, who met ICD-9 criteria for Feeding Difficulties as evidenced by feeding aversion, difficulty feeding, developmental delay in feeding, and extreme selectivity.

Key Points: 
  • Participants' children were male and female aged between birth and 4 years, who met ICD-9 criteria for Feeding Difficulties as evidenced by feeding aversion, difficulty feeding, developmental delay in feeding, and extreme selectivity.
  • Infants and children with pediatric feeding disorder experience difficulties eating, drinking, or digesting, which can result in the inability to get proper nutrition.
  • The complete manuscript, "Psychometric Properties of the Infant and Child Feeding Questionnaire" is available online here .
  • To learn more about pediatric feeding disorder, visit feedingmatters.org or follow us on Facebook, Instagram and YouTube at @FeedingMatters.